Larotrectinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-LAROTRECTINIB |
|---|---|
| Type | Drug |
| Aliases | VitrakviЛаротректініб |
| Status | pending_clinical_signoff |
| Diseases | DIS-IFS DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Drug Facts
| Class | TRK-selective inhibitor |
|---|---|
| Mechanism | Tumor-agnostic NTRK-fusion-targeted TKI. Highly active across NTRK1/2/3-fusion cancers including NSCLC. Not active in NTRK-WT. |
| Typical dosing | 100 mg PO BID. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
Cross-disease tumor-agnostic indication. NTRK testing universal in NSCLC NGS panels.
Used By
Regimens
REG-LAROTRECTINIB-IFS- Larotrectinib monotherapy (NTRK-fusion-positive infantile fibrosarcoma)REG-LAROTRECTINIB-PANTUMOR- Larotrectinib monotherapy (NAVIGATE / SCOUT) — NTRK fusion+ solid tumors (tumor-agnostic,...